Zydus Lifesciences Limited has released its financial results for the fourth quarter and the full fiscal year of 2024, showcasing impressive growth and operational success. The company’s revenue from operations reached Rs. 195,474 million for the year, marking a 13% increase from the previous year. The net profit saw a remarkable surge of 97%, totaling Rs. 38,595 million.

Q4 and Full-Year Financial Highlights

The fourth quarter continued this positive trend with revenues rising 10% year-over-year to Rs. 55,338 million. Net profit for the quarter was notably higher at Rs. 11,823 million, a 299% increase compared to the same period last year. EBITDA for the quarter stood at Rs. 16,305 million, up 30% year-over-year, with an EBITDA margin of 29.5%, improving by 440 basis points.

For the entire year, the EBITDA reached Rs. 53,843 million, a 40% increase, with an improved margin of 27.5%. Research & Development (R&D) investments accounted for 6.7% of revenues, amounting to Rs. 13,096 million, while the capital expenditure (Capex) for organic growth was Rs. 8,628 million.

Leadership’s Perspective on Future Growth

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, expressed satisfaction with the year’s robust performance, attributing it to strategic investments and operational efficiency. “We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and strive to improve EBITDA margins further from FY24 levels,” said Dr. Patel. He emphasized the company’s commitment to creating long-term value for stakeholders and positioning itself for future growth and innovation.

Zydus Lifesciences’ financial success is a testament to its focused approach on patient-centricity and diversified product portfolio, setting a strong foundation for continued success in the upcoming fiscal year.

  FY24 performance, pharmaceutical industry growth, Zydus annual report, Zydus Lifesciences, Zydus Lifesciences financial results